Q-omics provides the consensus-scored ANKRD23 profile across patient tissues and cancer cell-line models. ANKRD23 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ANKRD23 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ANKRD23 RNA expression shows 19,029 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where ANKRD23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD23 survival associations across molecular data types. ANKRD23 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD23 RNA expression–survival associations across cancer types. High ANKRD23 expression shows unfavorable associations in ACC, KICH, KIRC and LIHC, but favorable associations in BLCA and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ANKRD23 RNA expression.
This table summarizes ANKRD23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD23 shows lower tumor expression in KICH and HNSC and higher tumor expression in KIRC, COAD, LIHC and READ. The KIRC box plot shows higher ANKRD23 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p < 0.001).
This table shows molecular features associated with ANKRD23 in patient tissues and cancer cell lines. In patient samples, ANKRD23 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
